Abstract
PS assessment plays a major role in determining the investigations and treatments offered to patients with suspected or confirmed lung cancer.1 The National Lung Cancer Audit (NLCA) advices that 65% of patients with PS 0-1 and advanced (Stage 3B/4) Non-Small Cell Lung Cancer (NSCLC) should receive Systemic Anti-Cancer Treatment (SACT).
Aim: To assess the consistency of PS assessment of patients attending the lung cancer clinics between doctors, clinical nurse specialists (CNS’) and the self-assessment of the patients themselves and hence to validate the use of PS assessment in Lung cancer MDTs in making treatment decisions.
Method: Prospective survey of patients, doctors and lung cancer nurses scoring of the PS (WHO scale) at the first lung cancer clinic assessment and assessing concordance between the three groups. 49 consecutive patients attending lung cancer clinic in a UK District General Hospital.
Results: see table 1:
Conclusion: Though there is a degree of variation in PS assessment between the clinicians (doctors & CNS’) and patients’ self-assessment, there seemed to be concordance between the doctors and nurses. This observational study emphasises the importance of uniformity in PS assessment to deliver a patient centred care.
Reference:
1. JAMA Oncol. 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4654.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019